Promoted as healing shortcuts for tendons, ligaments, and even gut health, these compounds are gaining popularity among women searching for faster recovery, reduced inflammation, and more consistent training
This framework covers the majority of research compounds but is a starting point, not a substitute for compound-specific documentation
The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding, citing concerns such as immune reactions, peptide-related impurities, and limited safety information
Both employed an oral AOD-9604 formulation [2]
Women in this hormonal phase who start BPC-157 for musculoskeletal indications may see a longer ramp-up period before structural improvements become visible, because the tissue environment is working against faster healing from the hormonal side